Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04179266
Other study ID # 2019-001260-29
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received
Last updated
Start date November 20, 2019
Est. completion date May 25, 2020

Study information

Verified date February 2021
Source CCH Pharmaceuticals
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Ketamine has been used clinically IV in a very safe manner by a very small number of clinicians, to treat migraines and CH, and various other rarer pain disorders, including mixed headache and neuropathic pain clinical syndromes. In 5 cases taken from Krusz J.C. headache clinic data in Dallas, Texas US, an intranasal spray of ketamine aqueous solution of 100 µL in one nostril were dosed in treatment of patients with refractory chronic cluster headache as an alternative to IV-treatment (data not published).The net conclusion, at this point, is that intranasal ketamine is a legitimate pharmacologic treatment and is safe and has in one case series proven effective for CH rescue. The CCH patients will be dosed with an intranasal spray containing 172.5 mg ketamine hydrochloride (150 mg ketamine base) per ml in an aqueous solution. The individual dosing includes 15 mg ketamine in an intranasal sprayed volume of 100 µL given in one nose nostril under supervision of a nurse. The treatment is initiated at T0 under a CH attack when the headache pain exceeds NRS = 6 on an NRS pain scale. The first intranasal dose of 15 mg is given at time 0 and at time intervals of 6 minutes. At 15 minutes after 3 doses (45 mg) it is decided to evaluate whether the patient is sufficiently pain relieved (e.g. NRS < 4) or wants to receive rescue medications instead or if pain is not sufficiently relieved wants to continue until 5 dosing's (75 mg) are received at timepoints T24. The final evaluation of the treatment is performed at T30. Participants are followed up after 1-2 weeks by telehone


Recruitment information / eligibility

Status Completed
Enrollment 23
Est. completion date May 25, 2020
Est. primary completion date May 12, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: - Signed informed consent - Age between 18 and 60 years - Diagnose: Chronic cluster headache according to ICHD-3 criteria (1) - Body weight =50 kg and BMI =30 Exclusion Criteria: - Conditions that result in the participant being unable to complete the experiment - Medical history with elevated intraocular pressure (e.g. glaucoma) - Medical history with severe heart or liver disease - Aneurysmal vascular disease or arteriovenous malformations - Medical history with severe neurological disease except of headache - BP measured at baseline before CH attack (Systolic> 140 mmHg or / and diastolic blood pressure> 90 mm Hg) - Medical history with severe depression or psychosis - A previous history of drug abuse - Consumption of illegal drugs within the last 6 months - Medical history of nasal abnormality or dysfunction (e.g. rhinitis) - High disposition for larynges or apnea - Positive pregnancy test before treatment and breastfeeding - Known hypersensitivity to ketamine

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Ketamine
One Cluster headache attack is treated with intranasal ketamine

Locations

Country Name City State
Denmark Danish Headache Center Glostrup

Sponsors (2)

Lead Sponsor Collaborator
CCH Pharmaceuticals Danish Headache Center

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary Effect on pain intensity at 15 min (50% reduction) A 50% or more reduction in pain on a ten-point NRS scale (0: no pain, 10: worst imaginable pain) at T15 from pain intensity at T=0 . 15 minutes
Secondary Effect on pain intensity at 30 min A 50% or more reduction in pain on a ten-point NRS scale (0: no pain, 10: worst imaginable pain) at T30 from pain intensity at T=0. 30 minutes
Secondary Effect on pain intensity at 15 min (25% reduction) A 25% reduction in pain on a ten-point NRS scale (0: no pain, 10: worst imaginable in) at T15 from pain intensity at T=0. 15 minutes
Secondary Proportion of patients achieving NRS less than 4 at 15 minutes Proportion of patients achieving NRS less than 4 at 15 minutes 15 minutes
Secondary Proportion of patients achieving NRS less than 4 at 30 minutes Proportion of patients achieving NRS less than 4 at 30 minutes 30 minutes
Secondary Proportion of patients receiving rescue medication at 15 minutes Proportion of patients receiving rescue medication at 15 minutes 15 minutes
Secondary Proportion of patients preferring ketamine treatment compared to oxygen or injectable sumatriptan. Proportion of patients preferring ketamine treatment compared to oxygen or injectable sumatriptan. 180 minutes (entire attack)
Secondary Proportion of patients experiencing serious side effects during treatment Proportion of patients experiencing serious side effects during treatment one week follow-up.
See also
  Status Clinical Trial Phase
Recruiting NCT05264714 - Cluster Headache Treatment With Rimegepant Phase 2
Completed NCT01677026 - Data Collection on the ATI Neurostimulation System: SPG Stimulation for Cluster Headache
Terminated NCT00203190 - A Double-Blind, Placebo-Controlled Study Examining the Use of Topiramate in the Treatment of Cluster Headache Phase 4
Terminated NCT04570475 - High Dose Vitamin D Plus Multivitamin in the Prevention of Cluster Headache Phase 3
Completed NCT04066023 - Double-Blind Comparison of the Efficacy and Safety of C213 to Placebo for the Acute Treatment of Cluster Headaches Phase 2/Phase 3
Withdrawn NCT04353505 - Intra-arterial Sphenopalatine Ganglion Block for Patients With Refractory Headache Phase 1
Completed NCT02019017 - Botox Injection in Treatment of Cluster Headache Phase 1/Phase 2
Completed NCT05153876 - An Open Internet-based Survey and Natural Language Processing Project Analysing Written Monologues by Headache Patients
Recruiting NCT05324748 - Repeated GON Injections in CCH Phase 3
Completed NCT02782533 - DBS of the Third Ventricle for Cluster Headache and Obesity N/A
Recruiting NCT04406259 - Atrioventricular Block and Cluster Headache (SEVA) Phase 4
Recruiting NCT06206772 - Resting State Functional Connectivity in Cluster Headache
Recruiting NCT03944876 - Botulinum Toxin Type A Blockade of the Sphenopalatine Ganglion in Treatment-refractory Chronic Cluster Headache Phase 3
Not yet recruiting NCT05857098 - Detection of Local Field Potentials in the Ventral Tegmental Area of the Midbrain in Chronic Cluster Headache Patients
Recruiting NCT02910323 - The Will Erwin Headache Research Center - Cluster Headache Study
Terminated NCT00458770 - Study of Hypothalamic Metabolism in Spontaneous Cluster Headache Attacks N/A
Completed NCT00662935 - Evaluation of Efficacity and Safety of Deep Brain Stimulation (DBS) in Chronic and Treatment-Resistant Cluster Headache(CH) N/A
Active, not recruiting NCT03511846 - Pain Biomarker Study Phase 1
Completed NCT00184587 - Prophylactic Treatment of Episodic Cluster Headache Phase 2
Not yet recruiting NCT06277063 - nVNS for the Prevention and Treatment of Primary Headache N/A